Web of Science: 32 cites, Scopus: 38 cites, Google Scholar: cites,
Diacerein : Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel (Institute of Rheumatology and Clinic of Rheumatology, Charles University)
Bruyère, Olivier (Liège, Belgium)
Cooper, Cyrus (Southampton, UK)
Kanis, John A. (Sheffield, UK)
Leeb, Burkhard F. (2nd Department of Medicine, State Hospital Stockerau, Centre for Rheumatology, Lower Austria, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria)
Maheu, Emmanuel (Rheumatology Department, AP-HP, St-Antoine Hospital)
Martel-Pelletier, Johanne
Monfort, Jordi (Hospital del Mar)
Pelletier, Jean-Pierre (Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame-Hospital)
Rizzoli, René (Division of Bone Diseases, Geneva University Hospital and Faculty of Medicine)
Reginster, Jean-Yves (Department of Public Health, Epidemiology and Health Economics, University of Liège)
Universitat Autònoma de Barcelona. Departament de Medicina

Data: 2016
Resum: Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit-risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: article ; current opinion ; publishedVersion
Publicat a: Drugs & Aging, Vol. 33 (february 2016) , p. 75-85, ISSN 1179-1969

DOI: 10.1007/s40266-016-0347-4
PMID: 26849131

11 p, 634.6 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-02-07, darrera modificació el 2020-11-01

   Favorit i Compartir